Analysis of SARS-CoV-2 seroprevalence among the population of the Vladimir Region during the COVID-19 epidemic


DOI: https://dx.doi.org/10.18565/epidem.2021.11.2.29-35

Popova A.Yu., Ezhlova E.B., Melnikova A.A., Danilova T.E., Bulanov M.V., Lyalina L.V., Smirnov V.S., Totolyan A.A.

1) Russian Federal Service for Supervision of Consumer Rights Protection and Human Well-Being, Moscow, Russia; 2) Directorate for the Vladimir Region, Russian Federal Service for Supervision of Consumer Rights Protection and Human Well-Being, Vladimir, Russia; 3) Center for Hygiene and Epidemiology in the Vladimir Region, Vladimir, Russia; 4) Saint Petersburg Pasteur Research Institute of Epidemiology and Microbiology, Russian Federal Service for Supervision of Consumer Rights Protection and Human Well-Being, Saint Petersburg, Russia
Objective. To estimate the level of seroprevalence in the population of the Vladimir Region during the COVID-19 epidemic.
Materials and methods. Work was done as part of the first stage of the program to assess herd immunity to SARS-CoV-2 among the population of the Russian Federation according to the common methodology developed by the Russian Federal Service for Supervision of Consumer Rights Protection and Human Well-Being with the participation of the Pasteur Research Institute of Epidemiology and Microbiology. Volunteers were selected using questionnaires and randomization. The analysis included the results of a survey of 2,798 volunteers distributed in 7 age groups. The level of IgG specific to SARS-CoV-2 nucleocapsid was determined by enzyme immunoassay.
Results. The level of seroprevalence in the population was 10.7%, with a maximum of 25.1% in children aged 1-6 years and a minimum of 7.6% in people aged 18-29 years. No statistically significant differences were found between men and women in indicators. Specific antibodies were detected in 57.1% of the patients who had experienced COVID-19. Contact with a COVID-19 patient was accompanied by seroconversion 1.5 times more often than the population average. Seroconversion was 42.3% in asymptomatic individuals with positive PCR. Among the seropositive volunteers, the proportion of asymptomatic infection amounted to as much as 87.6%.
Conclusion. Low seroprevalence in the population contributed to the emergence of the second wave of COVID-19.
Keywords: Vladimir Region, seroprevalence, coronaviruses, SARS-CoV-2, population, morbidity
Read entire article

Literature

1. Kapikian A.Z. The coronaviruses. Dev. Biol. Stand. 1975; 28: 42–64. PMID: 1092577


2. Kristoffersen A.W., Nordbø S.A., Rognlien A.-G.W., Christensen A., Døllner H. Coronavirus causes lower respiratory tract infections less frequently than RSV in hospitalized Norwegian children Pediatr. Infect. Dis. J. 2011; 30(4): 279–83. doi: 10.1097/INF.0b013e3181fcb159


3. Peiris J.S.M., Lai S.T., Poon L.L.M., Guan Y., Yam L.Y.C., Lim W. Et al. Coronavirus as a possible cause of severe acute respiratory syndrome Lancet 2003; 361(9366): 1319–25. doi: 10.1016/S0140-6736(03)13077-2


4. Hui D.S.C., Zumla A. Severe Acute Respiratory Syndrome Historical, Epidemiologic, and Clinical Features. Infect. Dis. Clin. North Am. 2019; 33(4): 869–89.


5. Weekly epidemiological record. Relevé épidémiologique hebdomadaire 2003; 78(12): 81–8. https://www.who.int/docstore/wer/pdf/2003/wer7812.pdf


6. Zaki A.M., van Boheemen S., Bestebroer T.M., Osterhaus A.D.M.E., Fouchier R.A.M. Isolation of a novel coronavirus from a man with pneumonia in Saudi Arabia. N. Engl. J. Med. 2012; 367(19): 1814–20. doi: 10.1056/NEJMoa1211721


7. WHO. Middle East respiratory syndrome coronavirus (MERS-CoV). https://www.who.int/news-room/fact-sheets/detail/middle-east-respiratory-syndrome-coronavirus-(mers-cov)


8. Chan J.F.W., Lau S.K.P., To K.K.W., Cheng V.C.C., Woo P.C.Y., Yuen K.-Y. Middle East Respiratory Syndrome Coronavirus: Another Zoonotic Betacoronavirus Causing SARS-Like Disease. Clin. Microbiol. Rev. 2015; 28(2): 465–522. doi: 10.1128/CMR.00102-14


9. Ramshaw R.E., Letourneau I.D., Hong A.Y., Hon J., Morgan J.D., Osborne J.C.P. et al. A database of geopositioned Middle East Respiratory Syndrome Coronavirus occurrences. Sci Data 2019; (6): 318. doi: 10.1038/s41597-019-0330-0


10. Fagbule O.F., 2019 NOVEL CORONAVIRUS. Ann. Ib. Postgrad. Med. 2019; 17(2): 108–10. PMID: 32669985


11. WHO. Coronavirus disease 2019 [Internet]. World Health Organization. https://www.who.int/ emergencies/diseases/novel-coronavirus-2019


12. CDC. Coronavirus Disease 2019 (COVID-19) [Internet]. Center for Disease Control and Prevention. https://www.cdc.gov/coronavirus/2019- ncov/index.html. 2020. [cited 2020 Feb 14].


13. Смирнов В.С., Зарубаев В.В. Петленко С.В. Биология возбудителей и контроль гриппа и ОРВИ. СПб: Гиппократ, 2020. 334 c.

Smirnov V.S., Zarubaev V.V., Petlenko S.V. [Biology of pathogens and control of influenza and SARS]. Saint Petersburg: Hippocrates, 2020. 334 p. (In Russ.).


14. Yang D., Han Z., Oppenheim J.J. Alarmins and immunity. Immunol. Rev. 2017; 280(1): 41–56. doi: 10.1111/imr.12577


15. Смирнов В.С., Тотолян А.А. Врожденный иммунитет при коронавирусной инфекции. Инфекция и иммунитет 2020; 10(2): 259–68. doi: 10.15789/2220-7619-III-1440

Smirnov V.S., Totolyan A.A. [Congenital immunity in coronavirus infection]. Infection and immunity 2020; 10(2): 259–68. (In Russ.). doi: 10.15789/2220-7619-III-1440


16. Csepregi L., Ehling R.A., Wagner B., Reddy S.T. Immune literacy: reading, writing, and editing adaptive immunity. Science 2020; 23(9): 101519. doi: 10.1016/j.isci.2020.101519


17. Gavor E., Choong Y.K., Er S.Y., Sivaraman H., Sivaraman J. Structural Basis of SARS-CoV-2 and SARS-CoV Antibody Interactions. Trends in Immunol. 2020. doi: 10.1016/j.it.2020.09.004


18. Попова А.Ю., Ежлова Е.Б., Мельникова А.А., Башкетова Н.С., Фридман Р.К., Лялина Л.В. и др. Популяционный иммунитет к SARS-CoV-2 среди населения Санкт-Петербурга в период эпидемии COVID-19. Проблемы особо опасных инфекций 2020; (3): 124–30. DOI: 10.21055/0370-1069-2020-3-124-130

Popova A.Yu., Ezhlova E.B., Mel’nikova A.A., Bashketova N.S., Fridman R.K., Lyalina L.V. еt al. [Herd Immunity to SARS-CoV-2 among the Population in Saint-Petersburg during the COVID-19 Epidemic]. Problems of Particularly Dangerous Infections 2020; (3): 124–30. (In Russ.). DOI: 10.21055/0370-1069-2020-3-124-130


19. Newcombe R.G. Two-Sided Confidence Intervals for the Single Proportion: Comparison of Seven Methods. Statist. Med.  1998; 17: 857–87. doi: 10.1002/(sici)1097-0258(19980430)17: 857-887


20. Herroelen P.H., Martens G.A., De Smet D., Swaerts K., Decavele A.-S. Humoral Immune Response to SARS-CoV-2. Am. J. Clin. Pathol. 2020; 154(5): 610–9. doi: 10.1093/ajcp/aqaa140


21. Randolph H.E., Barreiro L. B Herd Immunity: Understanding COVID-19. Immunity 2020; 52(5): 737–41. doi: 10.1016/j.immuni.2020.04.012


22. Попова А.Ю., Ежлова Е.Б., Мельникова А.А., Оглезнева Е.Е., Красноперов А.С., Лялина Л.В. и др. Серопревалентность к SARS-CoV-2 среди населения Белгородской области на фоне эпидемии COVID-19. Эпидемиол. инфекц. болезни. Актуал. вопр. 2021; 11(1): 18–24. DOI: 10.18565/epidem.2021.11.1.18–24

Popovа A.Yu., Ezhlovа E.B., Melnikova A.A., Ogleznevа E.E., Krasnoperov A.S., Lyalina L.V. et al. [SARS-CoV-2 seroprevalence among the population of the Belgorod Region during the COVID-19 epidemic]. Epidemiology and infectious diseases. Сorrent items 2021; 11(1): 18–24 (In Russ.). DOI: 10.18565/epidem.2021.11.1.18–24


23. Snape M.D., Viner R.M. COVID-19 in children and young people. Science 2020; 370(6514): 286–88. DOI: 10.1126/science.abd6165


24. Fialkowski A., Gernez Y., Arya P. Weinacht K.G., Kinane T.B., Yonker L.M. Insight into the pediatric and adult dichotomy of COVID-19: Age related differences in the immune response to SARS-CoV-2 infection. Pediatric Pulmonology 2020; 55: 2556––64. Doi 10.1002/ppul.24981


About the Autors

Professor Anna Yu. Popova, МD, Head, Russian Federal Service for Supervision of Consumer Rights Protection and Human Well-Being, Moscow, Russia; depart@gsen.ru; https: orcid.org/0000-0002-4315-5307
Elena B. Еzhlova, Cand. Med. Sci., Deputy Head, Russian Federal Service for Supervision of Consumer Rights Protection and Human Well-Being, Moscow, Russia; ezhlova_eb@gsen.ru
Albina A. Melnikova, Cand. Med. Sci., Deputy Head, Directorate, Russian Federal Service for Supervision of Consumer Rights Protection and Human Well-Being, Moscow, Russia; melnikova_aa@gsen.ru; http://orcid.org/0000-0002-5651-1331
Tatiana E. Danilova, Head, Directorate for the Vladimir Region, Russian Federal Service for Supervision of Consumer Rights Protection and Human Well-Being, Vladimir, Russia; postmaster@33.rospotrebyfdzor.ru; http://orcid.org/0000-0003-3353-7173
Maksim V. Bulanov, Chief Physician, Center for Hygiene and Epidemiology in the Vladimir Region, Vladimir, Russia; sgm@vlades.vladinfo.ru; http://orcid.org/0000-0003-0349-0925
Professor Lyudmila V. Lyalina, МD, Head, Laboratory of Epidemiology of Communicable and Non-Communicable Diseases, Saint Petersburg Pasteur Research Institute of Epidemiology and Microbiology, Saint Petersburg, Russia; lyalina@pasteurorg.ru.; http://orcid.org/0000-0001-9921-3505
Professor Vyacheslav S. Smirnov, МD, Leading Researcher, Laboratory of Molecular Immunology, Saint Petersburg Pasteur Research Institute of Epidemiology and Microbiology, Saint Petersburg, Russia; vssmi@mail.ru; http://orcid.org/0000-0002-2723-1496
Professor Areg A. Totolyan, MD; Academician of the Russian Academy of Sciences, Director, Saint Petersburg Pasteur Research Institute of Epidemiology and Microbiology, Saint Petersburg, Russia; pasteur@pasteurorg.ru; https://orcid.org/0000-0003-4571-8799


Similar Articles

Back to Content

Бионика Медиа